Doing some rough calculations:
- USA GvHD market is expected to be 8x Japan's
- treatment cost is expected to be 1.25-2x cost of Temcell
- latest Japan revenue from Temcell is $6.6m usd ($9m aud)
- Projected annual USA revenue at 2020 levels therefore = $90m-$144m aud
-Assuming a p/e ratio of 41.8 (equivalent of csl) value of Rynocil approval gives a sp of: $6.43-$10.29 or a valuation of MSB of $3.762b-$6.019b
- Note that this excludes milestone payments, future Rynocil and Temcell earnings growth and any potential earning from future unapproved products including Covid-19 ARDS.
Doing some rough calculations:- USA GvHD market is expected to...
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.040(3.39%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $2.106M | 1.835M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 54850 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 4343 | 3 |
View Market Depth
| Last trade - 11.21am 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |